Tempus agrees to buy Personalis for USD 16.25 a share (about USD 1.5B) to add tumour-informed recurrence testing

Tempus AI/xT CDx genomic profiling

Tempus will acquire Personalis, whose NeXT Personal blood test looks for traces of a patient's cancer after treatment, for an enterprise value of about USD 1.5B. Tempus already sells the test under a 2023 partnership. The deal is mainly in stock and expected to close in late 2026 or early 2027.

• USD 16.25 per share; paid in stock, with Tempus able to pay up to half in cash.
• 28% premium to the 30-day average price.
• Personalis delivered 10,384 clinical tests in Q2 2026 (+33% on the quarter).
• Needs Personalis shareholder and regulatory approval.